SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Bought by Schroder Investment Management Group

Schroder Investment Management Group boosted its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 93.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 168,209 shares of the company's stock after purchasing an additional 81,314 shares during the period. Schroder Investment Management Group owned approximately 0.23% of SpringWorks Therapeutics worth $6,113,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. AlphaQuest LLC lifted its position in shares of SpringWorks Therapeutics by 70.2% during the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock worth $36,000 after purchasing an additional 414 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of SpringWorks Therapeutics in the 4th quarter valued at approximately $45,000. KBC Group NV raised its position in shares of SpringWorks Therapeutics by 59.1% in the 4th quarter. KBC Group NV now owns 2,634 shares of the company's stock valued at $95,000 after purchasing an additional 978 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of SpringWorks Therapeutics during the 3rd quarter valued at approximately $147,000. Finally, US Bancorp DE grew its position in shares of SpringWorks Therapeutics by 56.0% during the fourth quarter. US Bancorp DE now owns 4,336 shares of the company's stock worth $157,000 after buying an additional 1,556 shares in the last quarter.

Analyst Upgrades and Downgrades

SWTX has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $74.00 price target on shares of SpringWorks Therapeutics in a report on Friday, February 21st. Evercore ISI boosted their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Guggenheim reduced their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Finally, Wedbush reiterated an "outperform" rating and issued a $81.00 price target on shares of SpringWorks Therapeutics in a research note on Thursday, February 20th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SpringWorks Therapeutics has a consensus rating of "Buy" and an average price target of $73.20.

Remove Ads

SpringWorks Therapeutics Stock Up 3.9 %

SWTX stock traded up $1.41 during trading on Wednesday, hitting $37.12. 3,477,499 shares of the company's stock traded hands, compared to its average volume of 1,364,294. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of -10.67 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00. The stock has a fifty day moving average price of $48.70 and a two-hundred day moving average price of $40.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.38). The business had revenue of $61.55 million for the quarter, compared to the consensus estimate of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. As a group, equities research analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current fiscal year.

Insider Activity

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 29,750 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $54.36, for a total value of $1,617,210.00. Following the sale, the insider now owns 50,762 shares in the company, valued at approximately $2,759,422.32. This trade represents a 36.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bhavesh Ashar sold 1,016 shares of SpringWorks Therapeutics stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $61.19, for a total transaction of $62,169.04. Following the sale, the insider now owns 62,053 shares in the company, valued at approximately $3,797,023.07. This represents a 1.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 440,766 shares of company stock valued at $24,402,956. 7.61% of the stock is currently owned by insiders.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.